The risk of hypothyroidism after reduced-intensity hematopoietic cell transplantation (HCT) is not well known. We studied the incidence of hypothyroidism among a cohort of HCT recipients who had survived for X1 year and received a TBI-based myeloablative (MA) (N ¼ 84) or reduced-intensity (N ¼ 97) conditioning (RIC) regimen. MA HCT recipients were younger at the time of transplant (median age 37 vs 54 years, Po0.01), otherwise the two groups were comparable. Median follow-up was 28 (range, 12-75) months for MA and 25 (range, 12-67) months for RIC group. The 3-year cumulative incidence of hypothyroidism was 8 and 5%, respectively (P ¼ 0.41). In multivariate analysis, both types of conditioning regimens were associated with similar risks for hypothyroidism (relative risk for MA 1.6 vs RIC). At least in the first few years after HCT, the risks for hypothyroidism are similar among patients receiving TBI-based MA and reduced-intensity regimens.
Introduction
Hypothyroidism affects 9-15% of adult survivors of myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT). [1] [2] [3] [4] Risk factors include TBI, 1 age at transplantation 5 and GVHD. 6 Use of conditioning regimens that do not include TBI and use of fractionated instead of single-dose TBI may decrease the risk. Reducedintensity conditioning (RIC) regimens have been reported to be associated with lower transplant-related mortality and may have lower early and late morbidity compared with MA regimens. 7 However, the incidence of hypothyroidism among RIC HCT recipients has not been described. We conducted a retrospective cohort study of adult allogeneic HCT recipients to compare the incidence of hypothyroidism after transplantation using RIC and MA regimens.
Methods

Patient population
Consecutive patients who underwent an allogeneic HCT using either MA or RIC regimens between 2000 and 2005 at the University of Minnesota were included in this study if: (1) they were X18 years of age at the time of HCT, (2) had survived at least 1 year post transplant and (3) had no history of hypothyroidism pre-HCT. Patients on thyroid replacement therapy at the time of transplantation (N ¼ 10) and those receiving non-TBI-based conditioning regimens (N ¼ 9) were excluded. Transplant-related and outcome data were retrieved from the University of Minnesota Blood and Marrow Transplant Program Database, which prospectively collects these data on all patients transplanted at our institution. Additional data for this study were abstracted from patient medical records. Patients were treated according to clinical protocols approved by our institutional review board.
All patients are routinely followed up on our transplant program at scheduled intervals (100 days, and 6, 9, 12, 18 and 24 months) within the first 2 years after transplantation, with more frequent evaluation as medically indicated. All patients included in this study had thyroid studies (thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels) performed before HCT, and at 1 and 2 years after HCT. If clinically indicated, more frequent assessments were performed. All TSH and FT4 levels included in this study were measured at our hospital laboratory.
Conditioning regimen
Myeloablative and reduced-intensity conditioning regimens used at our institution have been described earlier. [8] [9] [10] Briefly, patients undergoing MA HCT received a regimen consisting of TBI and CY with or without fludarabine. RIC regimens consisted of TBI with either CY and fludarabine or BU and cladribine. The TBI dose in MA regimens was 1320 cGy (165 cGy twice daily Â 4 days) and in RIC regimens was 200 cGy (single fraction) without thyroid shielding. GVHD prophylaxis included CSA and either MTX or mycophenolate mofetil.
Study definitions
Hypothyroidism was classified as subclinical (elevated TSH and normal FT4) or overt (elevated TSH and low FT4). Patients with the following diagnoses were classified as having standard risk disease: acute leukemia in first CR, chronic myeloid leukemia in first chronic phase, myelodysplastic syndrome and non-malignant hematologic diseases; high-risk disease included all other diagnoses. HCT comorbidity index (HCT-CI) scores, as described by Sorror et al., 11 were retrospectively assigned to all patients and were categorized as low (score 0), intermediate (score [1] [2] or high (score X3).
Statistical analysis
Comparison of patient and transplant characteristics between MA and RIC groups was performed using w 2 , Fisher's exact or Wilcoxon's rank sum test, as appropriate. Cumulative incidence of hypothyroidism was calculated by treating deaths from any cause as a competing risk.
Competing risk and multivariate regression analysis was performed as described by Fine and Gray to evaluate potential risk factors for hypothyroidism. In addition to conditioning regimen intensity (MA vs RIC), variables considered in the multivariate model included age, ethnicity (white vs other), gender (male vs female), HCT-CI score at HCT (low vs intermediate vs high), donor type (related vs unrelated), grade 2-4 acute GVHD (yes vs no) and chronic GVHD (yes vs no). As all patients included in this study had survived for at least 1 year post HCT, acute and chronic GVHD were considered as categorical instead of time-dependent variables. Event times were measured from date of transplantation to date of death or last contact. All P-values were two sided. Analyses were performed using SAS 9.1 software.
Results
Study eligibility criteria were met by 181 patients (MA ¼ 84, RIC ¼ 97). Patient and transplant-related characteristics are described in Table 1 . MA HCT recipients were younger at HCT (median age 37 vs 54 years, Po0.01), but the two groups were otherwise comparable. Median follow-up was 28 (range, 12-75) months for MA and 25 (range, 12-67) months for RIC group. None of the patients had received an earlier HCT.
Overall, 11 patients developed hypothyroidism (subclinical 9, overt 2) with a 3-year cumulative incidence rate of 6% (95% confidence intervals (CI), 2-11%). Median time from HCT to development of hypothyroidism was 13 (range, 4-57) months. The 3-year cumulative incidence of hypothyroidism was 8% (95% CI, 1-14%) among MA and 5% (95% CI, 0-11%) among RIC HCT recipients (P ¼ 0.41) (Figure 1 ). TSH elevation was transient in three patients, and the remaining eight patients received thyroid hormone replacement therapy for persistent subclinical (N ¼ 6) or overt (N ¼ 2) hypothyroidism. The 3-year cumulative incidence of persistent hypothyroidism was 4% (95% CI, 1-8%) and included five MA and three RIC HCT recipients.
In multivariate analyses, similar risks for developing hypothyroidism were observed between the two conditioning regimens (relative risk for MA 1.6 (95% CI, 0.4-5.8; P ¼ 0.51) vs RIC). Female gender was the only factor predictive for development of hypothyroidism after allogeneic HCT (relative risk 4.5 (95% CI, 1.1-18.0; P ¼ 0.04) vs males). 
Discussion
We observed similar risks for hypothyroidism among recipients of TBI-based MA and RIC HCT. As the general population prevalence of hypothyroidism increases with age, 12 the advantage of lower dose of TBI in RIC regimens might be offset by the typical older age of RIC transplant recipients. Other factors such as family history, pretransplant exposures and type and dose of chemotherapy drugs used in conditioning regimen may also influence the risk of hypothyroidism in RIC HCT recipients.
TBI is a well established risk factor for hypothyroidism after MA HCT and use of fractionated instead of singledose TBI decreases its risk. 1 Only one other study has investigated the association of lower-dose TBI and hypothyroidism, although in MA HCT recipients. Al-Fiar et al., 2 in a retrospective cohort of 270 allogeneic HCT recipients, reported the incidence of hypothyroidism to be 3.2, 7.2, 16.7 and 11.7% among patients receiving HCT using conditioning regimens that included 300 cGy singledose TBI, 500 cGy single-dose TBI, 1200 cGy fractionated TBI and BU-CY only, respectively. However, there was no statistical difference between these groups. 2 Our study has certain limitations. We could not investigate all risk factors for hypothyroidism (for example, family history) given the retrospective nature of our study. The follow-up of our cohort is relatively short. However, hypothyroidism has been reported to typically occur within the first 2-3 years following MA HCT.
2-5 Also, our study did not include recipients of RIC regimens that do not utilize TBI. MA HCT recipients who receive chemotherapy-only conditioning regimens are also at risk for hypothyroidism; whether similar risks persist in patients receiving chemotherapy-only RIC regimens needs to be investigated.
In conclusion, at least in the first few years following HCT, patients receiving TBI-based RIC HCT have similar risks of hypothyroidism as those receiving MA HCT. Continuous monitoring of thyroid function is necessary in recipients of RIC HCT. 
